AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03388866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mite extract sublingual immunotherapy (SLIT)
Description: Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.
Study NCT03388866 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will be submitted to administration of increasing weekly doses, but with diluent of the allergenic extract (doubly distilled water solution and glycerin).
Study NCT03853538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Description: Product is applied to one hemiface.
Study NCT03853538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semisolid vaseline
Description: Product is applied to one hemiface.
Study NCT03870451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VascuTherm5 vascular compression device
Description: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device
Study NCT01406938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 150mg
Description: (1 injection per dose) and placebo to secukinumab 150 mg
Study NCT01406938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 300mg
Description: secukinumab 150 mg (2 injections per dose)
Study NCT04015427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant crown
Description: After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
Study NCT02186834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
Study NCT03853538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semisolid vaseline
Description: Product is applied to one hemiface.
Study NCT03897803 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: strain elastography
Description: strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.
Study NCT00106964 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B 20 mcg
Description: A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
Study NCT00106964 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B 40 mcg
Description: A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
Study NCT00106964 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg
Description: Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:~A single dose of 1 mL will be administered in the deltoid muscle.
Study NCT03267563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIAU
Description: Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
Study NCT03267563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LICF
Description: Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting.
Study NCT03267563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HICF
Description: Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
Study NCT02358135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Connected health, (CCH)
Description: CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
Study NCT03132298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implicit Theories of Personality Program
Description: This 30-minute, self-administered computer program teaches youths that personality is malleable, as opposed to fixed, due to the human brain's constant potential for change and growth (i.e., neuroplasticity).
Study NCT02358135 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
Study NCT02955823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab-Dexamethasone-Lenalidomide
Description: 1. st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~2. nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~   * if \<PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~  * if \<PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity.
Study NCT03486691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine measurement of left lobe
Description: Routine preoperative measurement of left lobe
Study NCT03486691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: no routine preoperative measurement of left lobe
Study NCT03855046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 50 U Intramuscular Powder for Solution
Description: Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution.
Study NCT03855046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral subcutaneous sphincterotomy.
Description: The patient is positioned on the table like for perineal lithotomy. After spinal anesthesia, the anal canal and then the surgical field are treated with 70% ethanol. Under the rectal speculum control, sparing surgical removal of fissure without internal sphincter incision is held using electrocoagulation.Then, in a 3 or 9 o'clock position, a narrow (eye) scalpel is inserted into the intersphincteric groove separating the external and internal sphincters, the scalpel blade is turned to the rectal lumen, and the internal sphincter is dissected up to the wall of the anal canal mucosa under the control of the finger inserted into the anal canal. After controlling hemostasis, the operation is ended with the introduction of the vent tube and hemostatic sponge.
Study NCT03206970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as specified in the treatment arm.
Study NCT03702959 — intervention group
Intervention type: DRUG
Intervention: Betamethasone
Description: Corticosteroids
Study NCT03230890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIRREM
Description: HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
Study NCT04653922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LinkCor Bioengineered Corneal Implant
Description: Intrastromal implantation of a bioengineered corneal equivalent device
Study NCT00413894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
Study NCT01289288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed printed materials and in-office training
Description: 1. Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster~2. Two sessions of in-office training with two standardized patients
Study NCT00374946 — intervention group
Intervention type: DEVICE
Intervention: THA
Study NCT00289068 — intervention group
Intervention type: PROCEDURE
Intervention: Phacoemulsification Sleeve surgery
Description: Group 2.2 mm surgery setting
Study NCT00289068 — intervention group
Intervention type: PROCEDURE
Intervention: Phacoemulsification Sleeves surgery
Description: Group 2.8 mm surgery setting
Study NCT00289068 — intervention group
Intervention type: PROCEDURE
Intervention: Phacoemulsification Sleeves
Description: Group 3.0 mm surgery setting
Study NCT01811485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMF237 50/250 mg
Description: Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
Study NCT01811485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMF237 50/500 mg
Description: Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
Study NCT03558386 — intervention group
Intervention type: BEHAVIORAL
Intervention: ePRO survey
Description: An electronic patient reported outcomes survey will be completed by the patient.
Study NCT03132298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Program
Description: This 30-minute, self-administered computer program was designed to control for nonspecific aspects of completing a series of computer-based activities in the context of the present study. It was also designed to mimic 'supportive therapy' that youths might receive in usual care settings, stressing the importance of sharing one's feelings with close others.
Study NCT00116649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod cream
Description: imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
Study NCT03914092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide injection
Description: ,1 mm percutaneous intralesional injection
Study NCT03914092 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smith Accent method of voice therapy
Description: regular sessions of smith accent voice therapy (about 24 sessions, twice session / week) for 3 months
Study NCT03748186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STRO-002
Description: intravenous antibody drug conjugate
Study NCT01688492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Abiraterone acetate (JanssenBiotech, Inc/Johnson \& Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
Study NCT04124887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride
Description: Sodium Fluoride varnish was applied to the targeted teeth at baseline, one and three months.
Study NCT04124887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricalcium Phosphate
Description: Varnish with Tricalcium Phosphate was applied to the targeted teeth at baseline, one and three months.
Study NCT04124887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol-coated calcium and phosphate
Description: Varnish with Xylitol-coated calcium and phosphate was applied to the targeted teeth at baseline, one and three months.
Study NCT04124887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate
Description: Varnish with Casein phosphopeptide amorphous calcium phosphate was applied to the targeted teeth at baseline, one and three months.
Study NCT02151877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
Study NCT02151877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
Study NCT01323712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D Cholecalciferol
Description: Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
Study NCT03954522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interview
Description: Child = A clinical interview (recorded, duration approximately 30 min) and a scale of acute stress (IES child) will be performed at 2 times (during the 7 days following the first visit of hospitalized kin and 1 month after the kin was discharged from ICU)~Accompanying parent/kin = Semi-directive interviews (recorded - duration approximately 30 min) will be performed at the same time as those of the child and will be recorded. The parent/kin will also complete a socio-demographic questionnaire of the family group and a depression anxiety scale (HADS)~Nursing staff = A semi-directive interview (recorded - duration approximately 30 min) will be performed only once (during the 7 days following the first visit to the hospitalized kin). The caregiver will also complete a socio-demographic questionnaire and a Moral Distress Scale (MDS-R)~Hospitalized parent = One month after ICU discharge, a depression anxiety scale (HADS) and an acute stress scale (IES) will be performed
Study NCT03705078 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transjugular Portosytemic Shunt (TIPS)
Description: The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.
Study NCT03705078 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: glue obliteration
Description: The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.
Study NCT03780829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypoxia
Description: intermittent cycles of normoxia-hypoxia
Study NCT03780829 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: hypoxia
Description: intermittent cycles of normoxia-hypoxia
Study NCT03780829 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham hypoxia
Description: intermittent cycles of sham hypoxia
Study NCT03780829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: NMDA agonist treatment
Study NCT03780829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sham-NMDA agonist
Description: sham-NMDA agonist treatment
Study NCT03780829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: bimanual massed practice training
Study NCT01811485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
Study NCT01490008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veregen
Description: Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
Study NCT03780829 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise training
Description: bimanual massed practice training
Study NCT03780829 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: exercise training
Description: bimanual massed practice training
Study NCT03769506 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ASP-1929 Photoimmunotherapy
Description: Use of ASP-1929 PIT therapy
Study NCT02295189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: anti-inflammatory injection
Study NCT02295189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: corticosteroid injection
Study NCT02673216 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03769506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice SOC
Description: docetaxel, cetuximab, methotrexate, paclitaxel
Study NCT02871219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01490008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals
Study NCT02976636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based behavioral therapy
Description: Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
Study NCT02976636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based behavioral therapy
Description: Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
Study NCT02976636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting training
Description: Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
Study NCT01942668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Study NCT01942668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Study NCT04422912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSG3-CAART or CABA-201
Description: Intravenous infusions of DSG3-CAART alone at different doses and different fractionations. Subjects may also receive varying doses of DSG3-CAART as part of a sub-study, which will employ pre-treatment with intravenous immunoglobulin, cyclophosphamide, and with or without fludarabine to potentially increase the in vivo expansion, persistence and activity of DSG3-CAART.~OR~CABA-201: Single intravenous infusion of CABA-201.
Study NCT04540224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-Cytometric analysis
Description: Measuring the level of serum IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p (70), IL-17A, IL-18, IL-23 and IL-33
Study NCT02871219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT03304639 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT03085407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early cholecystectomy
Description: cholecystectomy was done within 48 after admission